Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine added to lidocaine peribulbar block for cataract surgery
IRCT20210106049952N1Phase 2Completed
- Sponsor
- Research Institute of Ophthalmology
- Start
- Jan 2021
- Modality
- Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of neostigmine, lidocaine, hyaluronidase and saline in cataract (3 arms), sponsored by Research Institute of Ophthalmology. Primary endpoints: Hemodynamics, Onset of motor block and 1 more. Started Jan 2021; status: completed.
02
Drugs
neostigminelidocainehyaluronidasesaline
03
Conditions
cataract
Beyond the preview
Go deeper on IRCT20210106049952N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210106049952N1.